Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $141.10 | Total: $705.50 |
| 1 | 10 | $119.52 | Total: $1,195.20 |
| 1 | 25 | $101.26 | Total: $2,531.50 |
| 1 | 50 | $86.32 | Total: $4,316.00 |
| 1 | 100 | $74.70 | Total: $7,470.00 |
Overview
QL-X-138 HCl is a novel selective and highly potent BTKMNK dual-kinase inhibitor with anticancer activity that binds covalently to BTK and noncovalently to MNK. QL-X-138 HCl inhibited BTK, MNK1, and MNK2 kinases. QL-X-138 HCl has anti-dengue virus 2 activity and shows anti-proliferative activity in acute myeloid leukemia cells. QL-X-138 HCl can be used to study lymphoma and leukemia.
Chemical Properties
| Molecular Formula | C25H20ClN5O2 |
| Molecular Weight | 457.91 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C(NC1=CC(N2C(C=CC3=CN=C4C=CC(C5=CNN=C5)=CC4=C32)=O)=CC=C1C)C=C.Cl[H] |
Storage and Handling
0C Short Term, -20C Long Term
References
Wu H, et al. Discovery of a BTKMNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016 Jan;30[1] 173-81.